One stitch vs. none: can a simple change cut hernia pain?
NCT ID NCT06879860
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study compares two ways of placing a 3D mesh patch during inguinal hernia repair: fixing it with a single stitch versus not fixing it at all. The goal is to see which approach causes less chronic pain and fewer hernia recurrences. About 150 adults with a specific type of hernia will be followed for a year after surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- 3D mesh patch
- What this could lead to
- If successful, this could lead to a standard surgical technique that lowers chronic pain after hernia repair without increasing the chance of the hernia coming back.
- What could go wrong
- This is a relatively small trial (150 people) and results may not apply to all hernia types. The no-fixation group might have a higher recurrence risk, and pain outcomes depend on patient reporting.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INGUINAL HERNIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Nanchong Central Hospital
Nanchong, Sichuan, 637000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Which robot is faster for hernia surgery? a Head-to-Head test
- Robots vs. scalpels: can High-Tech hernia repair get you home sooner?
- One cut vs three: could a single incision make hernia surgery less painful?
- Could a muscle relaxant cut opioid use after hernia surgery?
- Exercise before and after hernia repair may speed recovery and reduce pain
- New hernia repair technique shows promise in 150-Patient trial